{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=47", "query": { "intervention": "Period B", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 1574, "total_pages": 158, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T22:21:18.882Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01092182", "title": "Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Burkitt Lymphoma", "Diffuse Large B-cell Lymphoma, c-MYC Positive", "Plasmablastic Lymphoma" ], "interventions": [ { "name": "EPOCH-R", "type": "DRUG" }, { "name": "EPOCH-RR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2010-03-25", "completion_date": "2023-02-16", "has_results": true, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 30, "location_summary": "La Jolla, California • Los Angeles, California • Atlanta, Georgia + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01092182" }, { "nct_id": "NCT03003520", "title": "A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-02-28", "completion_date": "2022-04-24", "has_results": true, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 7, "location_summary": "Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03003520" }, { "nct_id": "NCT04605484", "title": "Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BK Virus Nephropathy", "BK Virus Infection" ], "interventions": [ { "name": "Posoleucel (formerly known as ALVR105) cells", "type": "BIOLOGICAL" }, { "name": "Placebo (visually identical to Posoleucel)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2021-03-22", "completion_date": "2022-10-20", "has_results": true, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 33, "location_summary": "Los Angeles, California • Palo Alto, California • Sacramento, California + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04605484" }, { "nct_id": "NCT00586391", "title": "CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "CD19CAR-28-zeta T cells", "type": "GENETIC" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 14, "start_date": "2009-02", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586391" }, { "nct_id": "NCT00883558", "title": "Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin Lispro", "type": "DRUG" }, { "name": "regular human insulin", "type": "DRUG" }, { "name": "recombinant human hyaluronidase PH20", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2009-05", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 8, "location_summary": "Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Butte", "state": "Montana" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00883558" }, { "nct_id": "NCT02950025", "title": "Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Cancer of the Pancreas", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Online, adaptive MR-guided SBRT", "type": "DEVICE" }, { "name": "Online, non-adaptive MR-guided SBRT", "type": "DEVICE" }, { "name": "European Organization for Research and Treatment of Cancer (EORTC) QLQ-30", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-01-19", "completion_date": "2018-03-19", "has_results": true, "last_update_posted_date": "2019-04-03", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950025" }, { "nct_id": "NCT03825640", "title": "Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Open Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "CARE", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-01-14", "completion_date": "2020-01-15", "has_results": true, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 2, "location_summary": "Cranston, Rhode Island • Providence, Rhode Island", "locations": [ { "city": "Cranston", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03825640" }, { "nct_id": "NCT06238635", "title": "Dostarlimab and Cobolimab in Advanced Cervical Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Advanced Cervical Carcinoma", "Metastatic Cervical Cancer", "Metastatic Cervical Carcinoma", "Recurrent Cervical Carcinoma" ], "interventions": [ { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Cobolimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Meghan Shea", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 66, "start_date": "2024-03-11", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06238635" }, { "nct_id": "NCT03815058", "title": "A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Autogene cevumeran", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2018-12-21", "completion_date": "2025-01-21", "has_results": true, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 17, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03815058" }, { "nct_id": "NCT05312255", "title": "Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Plasma Cell Myeloma", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "Smoldering Plasma Cell Myeloma" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Beta-Adrenergic Antagonist", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Resistance Training", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2022-06-28", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-11-09", "last_synced_at": "2026-11-09T22:21:18.882Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05312255" } ] }